AbCellera Biologics Inc. disappointed analysts with lower-than-expected quarterly results. Analysts have revised forecasts, predicting a 37% revenue increase in 2025. Despite concerns, price targets vary widely, suggesting uncertainty about the company's future growth potential compared to industry averages.